Who Paid My Doc
Norman Waldrop
Foot and Ankle Surgery Birmingham, AL Medical Doctor
NPI 1184755621 CMS profile 281182
805 Saint Vincents Dr, Suite 100, Birmingham, AL 35205
General payments
$3,557,554
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$30,060
Through program year 2025, Norman Waldrop of Birmingham, AL is reported in the CMS Open Payments database as having received $3,557,554 across 370 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $30,060 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $814,077 | 76 | |
| 2024 | General | $920,823 | 72 | |
| 2023 | General | $488,580 | 43 | |
| 2022 | General | $437,873 | 33 | |
| 2021 | General | $406,048 | 28 | |
| 2020 | General | $256,610 | 29 | |
| 2019 | General | $233,542 | 89 |
Beside peers
- Norman Waldrop
- Foot and Ankle Surgery median
- Middle half of Foot and Ankle Surgery
- National median
In program year 2025, general payments to Norman Waldrop were reported at $814,077. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.
Show as a table
| Year | Norman Waldrop | Foot and Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $233,542 | $1,327 | $279–$5,421 | $163 |
| 2020 | $256,610 | $795 | $121–$3,473 | $114 |
| 2021 | $406,048 | $1,289 | $201–$4,963 | $132 |
| 2022 | $437,873 | $1,539 | $270–$6,067 | $149 |
| 2023 | $488,580 | $1,117 | $257–$5,264 | $160 |
| 2024 | $920,823 | $1,064 | $235–$4,944 | $164 |
| 2025 | $814,077 | $1,183 | $267–$6,309 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 8 drugsPart D claims
292
Drug cost
$9,689
Branded share of claims
53.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 13 | $7,199 | |
| Celecoxib | Generic | 17 | $741 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 104 | $596 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 39 | $426 | |
| Diclofenac Sodium | Generic | 30 | $401 | |
| Ondansetron Hcl | Generic | 27 | $142 | |
| Promethazine Hcl | Generic | 49 | $100 | |
| Gabapentin | Generic | 13 | $83 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 76 billing codesPaid by Medicare
$77,303
Medicare patients
190
Services billed
1,212
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 73% | |
| High blood pressure | 72% | |
| Diabetes | 25% | |
| Ischemic heart disease | 23% | |
| Depression | 23% | |
| Chronic kidney disease | 22% | |
| Osteoporosis | 17% | |
| Atrial fibrillation | 13% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 29 | 154 | $118 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
370 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Foot and Ankle Surgery in Alabama
Justin Daigre
Foot and Ankle Surgery · Decatur, AL
John Kirchner
Foot and Ankle Surgery · Hoover, AL
Jefferson Sabatini
Foot and Ankle Surgery · Huntsville, AL
Matthew Deorio
Foot and Ankle Surgery · Huntsville, AL
Ashish Shah
Foot and Ankle Surgery · Birmingham, AL
Alfred Ricci
Foot and Ankle Surgery · Montgomery, AL
Related records
Foot and Ankle Surgery in Alabama
Practitioners in the same specialty and state, ranked by reported value.
All Foot and Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Alabama
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.